Sebastian Haferkamp
Overview
Explore the profile of Sebastian Haferkamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
3573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forschner A, Kahler K, Gschnell M, Langan E, Weishaupt C, Meiss F, et al.
Front Immunol
. 2025 Mar;
16:1509886.
PMID: 40066437
Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life...
2.
Diab A, Ascierto P, Maio M, Abdel-Wahab R, Negrier S, Mortier L, et al.
J Clin Oncol
. 2025 Mar;
:JCO2400727.
PMID: 40048691
Purpose: There are limited treatment options for advanced melanoma that have progressed during or after immune checkpoint inhibitor therapy. Intratumoral (IT) immunotherapy may improve tumor-specific immune activation by promoting local...
3.
Braun L, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, et al.
Cancer Cell
. 2025 Feb;
43(2):269-291.e19.
PMID: 39933899
Immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors (ICIs) cause morbidity and necessitate cessation of treatment. Comparing irAE treatments, we find that anti-tumor immunity is preserved in...
4.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
5.
6.
Schreieder L, Zenderowski V, Berneburg M, Haferkamp S, Drexler K, Niebel D
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682200
With regard to excision of pigmented lesions for detection of malignant melanoma (MM), the number needed to treat (NNT) describes the number of melanocytic nevi that need to be biopsied/excised...
7.
Kott J, Zell T, Zimmermann N, Runger A, Smit D, Abeck F, et al.
Eur J Cancer
. 2024 Dec;
214():115159.
PMID: 39642845
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing anti-tumor treatment is through...
8.
Heinlein L, Maron R, Hekler A, Haggenmuller S, Wies C, Utikal J, et al.
Commun Med (Lond)
. 2024 Sep;
4(1):177.
PMID: 39256516
Background: Early detection of melanoma, a potentially lethal type of skin cancer with high prevalence worldwide, improves patient prognosis. In retrospective studies, artificial intelligence (AI) has proven to be helpful...
9.
Drexler K, Bollmann L, Karrer S, Berneburg M, Haferkamp S, Niebel D
Biology (Basel)
. 2024 Jul;
13(7).
PMID: 39056721
(1) Background: Rare skin cancers include epithelial, neuroendocrine, and hematopoietic neoplasias as well as cutaneous sarcomas. Ultraviolet (UV) radiation and sunburns are important drivers for the incidence of certain cutaneous...
10.
Zager J, Orloff M, Ferrucci P, Choi J, Eschelman D, Glazer E, et al.
Ann Surg Oncol
. 2024 Jul;
31(12):8262-8263.
PMID: 39026142
No abstract available.